A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders

Stefano Angelo Santini, Elena Rossi, Gian Ludovico Rapaccini, Mariapaola Marino, Enrico Di Stasio, Umberto Basile, Cecilia Napodano, Krizia Pocino, Federico Berruti, F. Gulli, M. A. Isgrò, L. Gragnani, L. Conti, I. Cordone, A. L. Zignego, G. Cigliana

Risultato della ricerca: Contributo in rivistaArticolo in rivista

5 Citazioni (Scopus)

Abstract

OBJECTIVE: Monoclonal plasma cell proliferative disorders comprise a wide spectrum of diseases associated to clonal B-cell expansion. Serum protein electrophoretic profile (SPEP) and circulating free light chains (FLCs) levels are the mainstay of diseases management. Recently, soluble (s) Syndecan-1 (SDC1, CD138) produced by myeloma plasma cells has been suggested in the monitoring and follow-up of patients with myeloma. The aim of our study is to evaluate sCD138 in addition with FLCs and SPEP for the screening of patients with different evolutive disease pathways. PATIENTS AND METHODS: Sera from 73 patients with monoclonal gammopathy of undetermined significance (MGUS), 120 smoldering and 42 multiple myeloma (SMM and MM, respectively), 70 HCV-related mixed cryoglobulinemia (MC), 35 B-cell non-Hodgkin’s lymphoma (B-NHL) and sera from 50 healthy donors (HD), were tested for sCD138, FLCs (assessed by means of ELISA and turbidimetric assay, respectively) and electrophoresis pattern (performed on Capillarys system) for the generation of a novel biomarker score (BS). RESULTS: Our results were grouped according to the two main lines of disease progression (vs. MM or B-NHL): in one group we found BS mean values of 0.2, 3.4, 5.3, 7.1 for HD, MGUS, SMM and MM, respectively; in the other group of 0.2, 4.4, 6.7 for HD, MC and B-NHL. CONCLUSIONS: We showed that BS mean values follow the ingravescence disease status towards the two main lines of progression to cancerous conditions; it could represent an additional useful tool in the management of screening and/or follow-up.
Lingua originaleEnglish
pagine (da-a)4293-4302
Numero di pagine10
RivistaEuropean Review for Medical and Pharmacological Sciences
Volume2019
DOI
Stato di pubblicazionePubblicato - 2019

Keywords

  • Biomarker, Free Light Chains, sCD138, Monoclonal Gammopathy,

Fingerprint Entra nei temi di ricerca di 'A novel biomarker score for the screening and management of patients with plasma cell proliferative disorders'. Insieme formano una fingerprint unica.

Cita questo